Table 1.
Characteristics of patients included into training and validation cohorts
| Parameter | Training cohort (n = 176) | Validation cohort (n = 486) | Total | |
|---|---|---|---|---|
| WHO diagnosis | BL | 16 | 13 | 29 |
| CLL | 20 | 125 | 145 | |
| DLBCL | 40 | 64 | 104 | |
| FL | 20 | 109 | 129 | |
| HCL | 20 | 38 | 58 | |
| LPL | 20 | 54 | 74 | |
| MCL | 20 | 56 | 76 | |
| MZL | 20 | 27 | 47 | |
| Gender | Female/male | 65/111 | 181/305 | 246/416 |
| Age (y) | Median (range) | 67 (2-93) | 65 (3-95) | 66 (2-95) |
| WBC (109/L)* | Median (range) | 8.1 (0.31-296) | 10 (0.8-217) | 9.4 (0.31-296) |
| % lymphoma cells† | Median (range) | 42.8 (0.12-99) | 41.6 (0.14-99) | 41.8 (0.12-99) |
| Disease phase | Diagnosis | 153 | 421 | 574 |
| Follow-up | 10 | 24 | 34 | |
| Relapse | 13 | 41 | 54 | |
| Sample type | PB | 55 | 201 | 256 |
| BM | 65 | 163 | 228 | |
| LN | 41 | 87 | 128 | |
| TM | 8 | 24 | 32 | |
| Other | 7 | 11 | 18 |
BM, bone marrow; LN, lymph node; PB, peripheral blood; TM, tumor mass; WBC, white blood count.
*
Exact WBC is not available for 125 cases.
†
As percentage of all leukocytes in sample.